Prices as of 2026/10/30 close
Company comparison · Mid-Tier Pharma & Drug Discovery
Nippon Shinyaku is the bigger company, with revenue of ¥170.8B — 9.2x Peptide Dream's ¥18.5B.
Nippon Shinyaku earns more on each yen of sales, with an operating margin of 20.8% — 47.9 points above Peptide Dream (-27.1%).
Revenue growth in the latest results: Nippon Shinyaku +6.6%, Peptide Dream −60.3%.
Peptide Dream pays more on average — ¥11.7M against ¥9.19M at Nippon Shinyaku.
Over the past year the shares moved Nippon Shinyaku +6.8%, Peptide Dream −28.4%.
Head-to-head wins13 metrics
One win per metric for the company with the best value. Metrics with no better or worse (P/E, average age, employees) are excluded.
ScaleInvestors
Nippon Shinyaku aheadNippon Shinyaku 3 : Peptide Dream 0
Revenue: Nippon Shinyaku ¥170.8B / Peptide Dream ¥18.5B
ProfitabilityInvestors
Nippon Shinyaku aheadNippon Shinyaku 2 : Peptide Dream 1
Operating margin: Nippon Shinyaku 20.8% / Peptide Dream −27.1%
GrowthInvestors
Peptide Dream aheadNippon Shinyaku 1 : Peptide Dream 2
Revenue growth (YoY): Nippon Shinyaku +6.6% / Peptide Dream −60.3%
Stock & balance sheetInvestors
EvenNippon Shinyaku 1 : Peptide Dream 1
Share price, 1 year: Nippon Shinyaku +6.8% / Peptide Dream −28.4%
Pay & workforceJob seekers
EvenNippon Shinyaku 1 : Peptide Dream 1
Average salary: Nippon Shinyaku ¥9.19M / Peptide Dream ¥11.7M
| Metric | Nippon Shinyaku | Peptide Dream | Gap |
|---|---|---|---|
| Revenue | ◎¥170.8B | ¥18.5B | 9.2x |
| Operating profit | ◎¥35.5B | −¥5.0B | |
| Net income | ◎¥29.7B | −¥3.7B |
| Metric | Nippon Shinyaku | Peptide Dream | Gap |
|---|---|---|---|
| Operating margin | ◎20.8% | −27.1% | 47.9pt |
| Net margin | ◎17.4% | −20.2% | 37.6pt |
| Revenue per employee | ¥91M | ◎¥118M | 1.3x |
| Metric | Nippon Shinyaku | Peptide Dream | Gap |
|---|---|---|---|
| Revenue growth (YoY) | ◎+6.6% | −60.3% | 66.9pt |
| Operating profit growth (YoY) | +0.1% | — | |
| Revenue CAGRlast 5 years | +7.0% | ◎+18.6% | 11.6pt |
| Guidance: revenue growthnext FY plan | +17.1% | ◎+72.8% | 55.7pt |
| Guidance: op. profit growthnext FY plan | +7.1% | — |
| Metric | Nippon Shinyaku | Peptide Dream | Gap |
|---|---|---|---|
| Share price, 1 year | ◎+6.8% | −28.4% | 35.3pt |
| Share price, 3 months | −1.7% | ◎+19.2% | 20.9pt |
| Share price (close) | ¥3,436 | ¥1,117 |
◎ marks the best value for each metric. Revenue and profit are from the latest full-year earnings release; share prices are closing-price references; P/E = latest close ÷ trailing EPS. For banks and some other financials, revenue means ordinary income.
| Metric | Nippon Shinyaku | Peptide Dream | Gap |
|---|---|---|---|
| Average salary | ¥9.19M | ◎¥11.7M | ¥2.50M |
| Starting salary (monthly) | ¥279,000 | — | |
| Average tenure | ◎17.2 yrs | 5.3 yrs | 11.9 |
| Average age | 41.4 | 39.7 | 1.7 |
| Employees | 1,876 | 157 | 11.9x |
Average salary is for the reporting (parent) company and is affected by average age and job mix. Holding companies with few employees are left out of the salary comparison.
Close (Oct 30, 2026)
¥3,436+6.8% (1Y)
Nippon Shinyaku +6.8% over 1Y. Compared: Peptide Dream -28.4%.
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Each line shows the % change from the start of the period. Updated Oct 30, 2026.
Nippon Shinyaku2 segments
Peptide Dream2 segments
AAverage annual salary from the securities filings: Peptide Dream ¥11.7M, Nippon Shinyaku ¥9.19M. Peptide Dream pays the most. Averages also depend on staff age and job mix, so check the average age too (Nippon Shinyaku 41.4, Peptide Dream 39.7).
ARevenue in the latest results: Nippon Shinyaku ¥170.8B, Peptide Dream ¥18.5B. Nippon Shinyaku is the bigger company, with revenue of ¥170.8B — 9.2x Peptide Dream's ¥18.5B.
AOperating margins: Nippon Shinyaku 20.8%, Peptide Dream -27.1%. Nippon Shinyaku turns the highest share of sales into operating profit.
AShare price change over the past year (closing prices, for reference): Nippon Shinyaku +6.8%, Peptide Dream −28.4%. Nippon Shinyaku has risen the most.
Comparing 2 companies (up to 4)
Sources: earnings releases (kessan tanshin), annual securities reports and other public information. Share prices are closing-price references, not real-time. Our data may contain errors; investment decisions are your own responsibility.
